165,890 Shares in NeoGenomics, Inc. $NEO Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 165,890 shares of the medical research company’s stock, valued at approximately $1,281,000. Y Intercept Hong Kong Ltd owned 0.13% of NeoGenomics as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in NEO. Greenhouse Funds LLLP raised its position in shares of NeoGenomics by 57.8% in the second quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock valued at $54,322,000 after purchasing an additional 2,722,823 shares during the period. Cubist Systematic Strategies LLC bought a new position in NeoGenomics in the 2nd quarter worth approximately $6,071,000. First Light Asset Management LLC grew its stake in NeoGenomics by 13.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,846,432 shares of the medical research company’s stock valued at $50,047,000 after buying an additional 803,610 shares in the last quarter. Squarepoint Ops LLC raised its holdings in NeoGenomics by 246.8% during the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company’s stock valued at $5,376,000 after acquiring an additional 523,407 shares during the period. Finally, HighMark Wealth Management LLC raised its holdings in NeoGenomics by 221.3% during the 3rd quarter. HighMark Wealth Management LLC now owns 400,334 shares of the medical research company’s stock valued at $3,091,000 after acquiring an additional 275,734 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NEO has been the subject of a number of analyst reports. Leerink Partners set a $14.00 price target on NeoGenomics in a report on Tuesday, October 28th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, January 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of NeoGenomics in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.00.

Insider Activity at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares of the company’s stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alicia C. Olivo sold 20,916 shares of NeoGenomics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the sale, the executive vice president directly owned 31,083 shares of the company’s stock, valued at $372,996. This represents a 40.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.40% of the company’s stock.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $12.06 on Friday. The stock’s 50-day simple moving average is $12.27 and its two-hundred day simple moving average is $9.62. NeoGenomics, Inc. has a twelve month low of $4.72 and a twelve month high of $14.88. The firm has a market capitalization of $1.56 billion, a P/E ratio of -13.70 and a beta of 1.58. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.